Malignant Pleural Effusion Patients Needed
Are you interested in exploring an alternative investigational treatment strategy for your patients with late-stage, breast, ovarian,or non-small cell lung cancer (NSCLC) with malignant pleural effusion?
Clinical Study Recruiting Patients!
We’re seeking participants to join an open-label, Phase II Expansion Study (MITOPE), aimed at assessing the efficacy and safety of a novel anticancer agent – RSO-021 – in patients with advanced cancer and few remaining treatment options.
Preclinical evidence suggests that RSO-021 targets mitochondrial peroxiredoxin 3 (PRX3), a protein that helps shield malignant mitochondrial cells against damage from byproducts of oxygen metabolism. By binding to PRX3 and boosting oxidative stress, RSO-021 is believed to selectively destroy malignant cells whilst simultaneously sparing healthy ones.
About the Trial
Patients must be 18 years of age or older and have received one prior standard of care (SoC) treatment for advanced breast, ovarian, or NSCLC with documented progression and no approved life extending alternatives. All patients should not have had prior pleurodesis and are expected to drain at least 100ml pleural fluid. Participants will receive concomitant RSO-021 -- administered weekly via an intrapleural catheter -- and SoC intravenous paclitaxel administered every 3 weeks following the first dose.
Multiple NHS Trial Sites Throughout the UK
The RSO-021 plus paclitaxel Cohort 2 Study is being conducted at multiple, conveniently-accessed NHS sites throughout the UK. Travel will be compensated.
Guy’s Hospital® London
St. Bartholomew’s Hospital® London
St. James Hospital® Leeds
The Christie® Manchester
University of Leicester
The Scotland Institute-Glasgow®